Article info
PDFColorectal
Original research
Ustekinumab for the treatment of moderate to severe ulcerative colitis: a multicentre UK cohort study
- Correspondence to Dr Sailish Honap, IBD Centre, 1st Floor College House, Westminster Bridge Road, Guy's and St Thomas' NHS Foundation Trust, London SE1 7EH, UK; shonap{at}nhs.net
Citation
Ustekinumab for the treatment of moderate to severe ulcerative colitis: a multicentre UK cohort study
Publication history
- Received March 14, 2022
- Accepted April 18, 2022
- First published April 28, 2022.
Online issue publication
January 23, 2024
Article Versions
- Previous version (7 October 2022).
- You are viewing the most recent version of this article.
Supplementary Data
This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Author(s) (or their employer(s)) 2022. No commercial re-use. See rights and permissions. Published by BMJ.